A carregar...
Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on the US pharmaceutical market; some of them also...
Na minha lista:
| Publicado no: | Pharmaceutics |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7761673/ https://ncbi.nlm.nih.gov/pubmed/33287305 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics12121180 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|